My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Gemtuzumab Biosimilar, CD33 Monoclonal Antibody

Gemtuzumab Biosimilar, CD33 Monoclonal Antibody

Siglec-3, sialic acid binding Ig-like lectin 3, SIGLEC3, gp67, p67

Catalog No. Product Name Size List Price (US$) Quantity
C049P Gemtuzumab Biosimilar, CD33 Monoclonal Antibody 1 mg 250.00
C049P Gemtuzumab Biosimilar, CD33 Monoclonal Antibody 5 mg 750.00
C049P Gemtuzumab Biosimilar, CD33 Monoclonal Antibody 20 mg 2000.00
C049P.05 Gemtuzumab Biosimilar, Endotoxin 0.05 EU/mg 5 mg 1125.00
C049P.05 Gemtuzumab Biosimilar, Endotoxin 0.05 EU/mg 20 mg 3000.00

C049P: Gemtuzumab Biosimilar, CD33 Monoclonal Antibody

Recombinant Humanized IgG4 Monoclonal Antibody.
Isotype: Human IgG4 kappa.
Source: The anti-human CD33 monoclonal antibody gemtuzumab biosimilar was produced in the gemtuzumab biosimilar CHO stable cell line.
Specificity/Sensitivity: The in vivo grade gemtuzumab biosimilar specifically binds to the human CD33 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by gemtuzumab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade gemtuzumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.


Gemtuzumab is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody Label. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death.

Gemtuzumab is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Gemtuzumab with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in site-specific DNA double strand breaks via formation of a p-benzene diradical. Eventually, cell death is induced.

Syd Labs provides the following research grade antibody biosimilars used in ADCs:
Tusamitamab biosimilar, research grade, anti-human CEACAM5 monoclonal antibody
Rovalpituzumab biosimilar, research grade, anti-human DLL3 monoclonal antibody
Trastuzumab biosimilar, research grade, anti-human HER2 monoclonal antibody
Cofetuzumab biosimilar, research grade, anti-human PTK7 monoclonal antibody
Ifinatamab biosimilar, research grade, anti-human B7-H3 (CD276) monoclonal antibody
Sacituzumab biosimilar, research grade, anti-human Trop-2 monoclonal antibody
Gemtuzumab biosimilar, research grade, anti-human CD33 monoclonal antibody
Polatuzumab biosimilar, research grade, anti-human CD79B monoclonal antibody
Cetuximab biosimilar, research grade, anti-human EGFR monoclonal antibody

Related Links

See our Privacy Policy